Mesoblast Ltd (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.34 billion
P/E Ratio 0.14
Dividend Yield 0.00%
Shares Outstanding 1.14 billion
Earnings per share -0.087
Dividend per share N/A
Year To Date Return 279.03%
Earnings Yield 711.28%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mesoblast Ltd (ASX: MSB)
    Latest News

    Scientists working in the laboratory and examining results.
    Healthcare Shares

    Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

    This high-flying share is still reporting insider buying. Should you buy too?

    Read more »

    Emotional euphoric young woman giving high five to male partner, celebrating family achievement, getting bank loan approval, or financial or investing success.
    Share Gainers

    If you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!

    Mesoblast shares have been soaring higher over the past six weeks. But why?

    Read more »

    Man puts hands in the air and cheers with head back while holding phone and coffee
    Broker Notes

    9 ASX All Ords shares elevated to 'strong buy' status in April

    Let's check them out.

    Read more »

    A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
    Share Fallers

    Why Aeris Resources, Mesoblast, Pointsbet, and Worley shares are sinking today

    These shares are having a poor session on Tuesday. But why?

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Healthcare Shares

    Why is the Mesoblast share price taking a dive on Tuesday?

    This high-flying share is under pressure today. But why?

    Read more »

    drug capsule opening up to reveal dollar signs signifying rising asx share price
    Share Gainers

    If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!

    Mesoblast shares have been on a tear this past month. But why?

    Read more »

    Person handing out $50 notes, symbolising ex-dividend date.
    Share Market News

    Insiders are buying Mesoblast and these ASX shares

    Insiders seem to see value in these shares.

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Cardno, Mesoblast, Perseus, and Somnomed shares are dropping today

    These ASX shares are having a tough hump day. But why?

    Read more »

    A happy couple looking at an iPad feeling great as they watch the Challenger share price rise
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    Why is everyone talking about Mesoblast shares?

    ASX biotech share Mesoblast has been grabbing plenty of investor attention recently.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the Mesoblast share price can rise another 60%

    The big gains may not be over according to Bell Potter.

    Read more »

    Woman in celebratory fist move looking at phone
    Broker Notes

    Brokers name 3 ASX shares to buy now

    Here's why brokers are feeling bullish about these three shares this week.

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Ltd

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    MSB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $1.18 $0.00 0.00% 8,934,738 $1.18 $1.20 $1.14
    23 May 2024 $1.18 $0.03 2.61% 8,196,395 $1.14 $1.19 $1.14
    22 May 2024 $1.15 $0.02 1.78% 7,186,088 $1.16 $1.19 $1.13
    21 May 2024 $1.13 $0.05 4.65% 5,444,826 $1.08 $1.13 $1.07
    20 May 2024 $1.08 $-0.01 -0.92% 2,961,584 $1.10 $1.11 $1.06
    17 May 2024 $1.09 $0.06 5.85% 6,038,289 $1.03 $1.10 $1.02
    16 May 2024 $1.03 $-0.03 -2.86% 5,571,955 $1.06 $1.06 $1.02
    15 May 2024 $1.05 $-0.01 -0.94% 3,978,990 $1.09 $1.09 $1.05
    14 May 2024 $1.07 $0.02 1.91% 3,797,380 $1.04 $1.07 $1.04
    13 May 2024 $1.05 $-0.02 -1.88% 6,155,505 $1.08 $1.08 $1.02
    10 May 2024 $1.07 $-0.03 -2.75% 7,517,387 $1.10 $1.13 $1.05
    09 May 2024 $1.09 $-0.04 -3.54% 9,616,881 $1.12 $1.14 $1.09
    08 May 2024 $1.13 $-0.05 -4.26% 10,699,296 $1.18 $1.19 $1.12
    07 May 2024 $1.18 $0.02 1.73% 14,047,015 $1.20 $1.21 $1.17
    06 May 2024 $1.16 $0.07 6.45% 17,944,902 $1.12 $1.20 $1.11
    03 May 2024 $1.09 $0.01 0.93% 10,528,006 $1.11 $1.12 $1.08
    02 May 2024 $1.07 $-0.03 -2.73% 29,220,535 $1.11 $1.21 $1.05
    01 May 2024 $1.10 $0.11 11.11% 22,061,544 $0.97 $1.11 $0.96
    30 Apr 2024 $0.99 $-0.10 -9.22% 25,912,213 $1.12 $1.12 $0.98
    29 Apr 2024 $1.09 $0.16 17.20% 27,375,536 $0.95 $1.09 $0.94

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    08 May 2024 Eric Rose Buy 19,734 $151,207
    On-market trade. US$
    30 Apr 2024 Eric Rose Buy 21,428 $142,318
    On-market trade. US$ ADS
    12 Apr 2024 Jane Bell Buy 233,918 $199,999
    On-market trade.
    10 Jan 2024 William (Bill) Burns Issued 409,651 $116,750
    Issue of options.
    10 Jan 2024 Jane Bell Issued 326,729 $93,117
    Issue of options.
    10 Jan 2024 Joseph Swedish Issued 827,077 $235,716
    Issue of options.
    10 Jan 2024 Eric Rose Issued 1,960,765 $558,818
    Issue of options.
    10 Jan 2024 Silviu Itescu Issued 3,693,070 $1,052,524
    Issue of options.
    10 Jan 2024 Philip Facchina Issued 290,432 $82,773
    Issue of options.
    29 Dec 2023 Joseph Swedish Buy 850 $917
    On-market trade. US$
    28 Dec 2023 Jane Bell Issued 61,905 $18,571
    Rights issue.
    28 Dec 2023 Joseph Swedish Buy 91,035 $99,082
    On-market trade. US$
    28 Dec 2023 William (Bill) Burns Issued 21,250 $6,375
    Rights issue.
    28 Dec 2023 Philip Krause Buy 37,500 $41,536
    On-market trade. US$
    21 Dec 2023 Philip Facchina Sell 30,000 $32,395
    On-market trade. US$, As per announcement on 28-12-2023
    12 Dec 2023 Silviu Itescu Issued 10,000,000 $3,000,000
    Rights issue.
    07 Jul 2023 Silviu Itescu Issued 2,325,000 $2,627,250
    Issue of options.
    07 Jul 2023 Eric Rose Issued 2,150,000 $2,429,500
    Issue of options.
    05 Jun 2023 Philip Krause Buy 20,000 $74,100
    On-market trade. US$, 100,000 ordinary shares held in the form of 20,000 ADSs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Silviu Itescu Chief Executive OfficerExecutive Director Jun 2004
    Dr. Itescu has served on the Board of Directors since the Company's founding. Dr Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy.
    Dr Eric A Rose Non-Executive Director Apr 2013
    Dr. Rose is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon in Chief of Columbia Presbyterian Medical Center in New York.
    Mr William (Bill) A Burns Non-Executive DirectorVice-Chairman Mar 2014
    Mr. Burns pent his entire management career at the Beecham Group and F. Hoffmann La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann La Roche until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016.
    Ms Jane Catherine Bell Non-Executive Director Aug 2022
    Ms. Bell is a banking and finance lawyer with 30 years experience in international law firms, financial services and corporate treasury operations focusing on international investment transactions in the United States, Canada, Australia and the United Kingdom. She has served as a non executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management.
    Mr Joseph R Swedish Non-Executive DirectorNon-Executive Chairman Jun 2018
    Mr Swedish has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector's most senior level executives, highlevel government administrators, elected officials, academics, and thought leaders for five consecutive years. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems.
    Mr Philip J. Facchina Non-Executive Director Mar 2021
    Mr. Facchina brings more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take privates.
    Dr Philip R Krause Non-Executive Director Mar 2022
    With over 30 years of experience at the Food and Drug Administration, Dr. Krause has a unique combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011 to 2021.
    Ms Niva Sivakumar Joint Company Secretary Oct 2019
    -
    Mr Paul Hughes Joint Company Secretary Apr 2022
    -
    Andrew Chaponnel Chief Financial Officer (interim)
    -
    Dagmar Rosa Bjorkeson Chief Operating Officer
    -
    Peter Howard General Counsel
    -
    Justin Horst Head of Manufacturing
    -
    Geraldine Storton Head of Regulatory Affairs and Quality Management
    -
    Niva Sivakumar Joint Company Secretary
    -
    Paul Hughes Joint Company Secretary
    -
    Michael Schuster Pharma Partnering
    -
    Paul Simmons Scientific Advisor to the Chief Executive Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 203,355,244 25.04%
    Hsbc Custody Nominees (Australia) Limited 84,795,597 10.44%
    Professor Silviu Itescu 67,751,838 8.34%
    Citicorp Nominees Pty Limited 36,878,513 4.54%
    Ubs Nominees Pty Ltd 14,530,688 1.79%
    Bnp Paribas Noms Pty Ltd 12,675,143 1.56%
    Thorney Holdings Pty Ltd 10,000,000 1.23%
    Tiga Trading Pty Ltd 10,000,000 1.23%
    Independent Asset Management Pty Limited 7,585,558 0.93%
    Merrill Lynch (Australia) Nominees Pty Limited 5,611,867 0.69%
    National Nominees Limited 4,014,582 0.49%
    Mr Gregory John Matthews & Mrs Janine Marie Matthews 3,841,063 0.47%
    Bnp Paribas Nominees Pty Ltd 3,484,343 0.43%
    Mann Securities Pty Ltd 2,352,942 0.29%
    Lalp Pty Ltd 1,647,144 0.20%
    Dr Siong Wei Hong 1,501,886 0.18%
    Irwin Biotech Nominees Pty Ltd 1,400,000 0.17%
    Beth Sackstein 1,277,210 0.16%
    Mr Muthiah John Hilbert 1,240,801 0.15%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 1,204,900 0.15%
    Mr Fei Tian 1,200,000 0.15%

    Profile

    since

    Note